NO329896B1 - Farmasoytisk sammensetning og anvendelse derav - Google Patents

Farmasoytisk sammensetning og anvendelse derav Download PDF

Info

Publication number: NO329896B1
Authority: NO; Norway
Prior art keywords: sumatriptan; headache; present; weight; equal
Prior art date: 2001-12-05

Application number

NO20025805A

Other languages

English (en)

Norwegian (no)

Other versions

NO20025805D0 (no

NO20025805L (no

Inventor

Simon John Summers

Robert William Baker

Alan David Dow

Julian Westrup

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-05

Filing date

2002-12-03

Publication date

2011-01-24

2002-12-03 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2002-12-03 Publication of NO20025805D0 publication Critical patent/NO20025805D0/no

2003-06-06 Publication of NO20025805L publication Critical patent/NO20025805L/no

2011-01-24 Publication of NO329896B1 publication Critical patent/NO329896B1/no

Links

239000008194 pharmaceutical composition Substances 0.000 title description 2
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 102
229960003708 sumatriptan Drugs 0.000 claims description 95
239000000203 mixture Substances 0.000 claims description 50
238000002360 preparation method Methods 0.000 claims description 46
206010019233 Headaches Diseases 0.000 claims description 36
231100000869 headache Toxicity 0.000 claims description 36
239000000825 pharmaceutical preparation Substances 0.000 claims description 29
239000002552 dosage form Substances 0.000 claims description 25
150000003839 salts Chemical class 0.000 claims description 25
208000019695 Migraine disease Diseases 0.000 claims description 23
239000000945 filler Substances 0.000 claims description 20
239000002585 base Substances 0.000 claims description 16
206010027599 migraine Diseases 0.000 claims description 16
230000002378 acidificating effect Effects 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 12
238000011282 treatment Methods 0.000 claims description 12
239000012453 solvate Substances 0.000 claims description 10
239000004480 active ingredient Substances 0.000 claims description 9
239000002360 explosive Substances 0.000 claims description 9
229920002785 Croscarmellose sodium Polymers 0.000 claims description 8
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
229960001681 croscarmellose sodium Drugs 0.000 claims description 8
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 8
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
239000008108 microcrystalline cellulose Substances 0.000 claims description 8
229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 7
239000007884 disintegrant Substances 0.000 claims description 7
238000003756 stirring Methods 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 5
208000006561 Cluster Headache Diseases 0.000 claims description 4
206010072720 Medication overuse headache Diseases 0.000 claims description 4
206010043269 Tension headache Diseases 0.000 claims description 4
208000008548 Tension-Type Headache Diseases 0.000 claims description 4
208000018912 cluster headache syndrome Diseases 0.000 claims description 4
210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
239000004081 narcotic agent Substances 0.000 claims description 4
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
208000019553 vascular disease Diseases 0.000 claims description 4
206010009094 Chronic paroxysmal hemicrania Diseases 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
208000035475 disorder Diseases 0.000 claims description 3
239000012458 free base Substances 0.000 claims description 3
210000004051 gastric juice Anatomy 0.000 claims description 3
208000007777 paroxysmal Hemicrania Diseases 0.000 claims description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
239000001506 calcium phosphate Substances 0.000 claims 1
229910000389 calcium phosphate Inorganic materials 0.000 claims 1
235000011010 calcium phosphates Nutrition 0.000 claims 1
239000003826 tablet Substances 0.000 description 37
238000009472 formulation Methods 0.000 description 36
239000007787 solid Substances 0.000 description 25
KQKPFRSPSRPDEB-XERRXZQWSA-N 1-[3-[2-[bis(trideuteriomethyl)amino]ethyl]-1h-indol-5-yl]-n-methylmethanesulfonamide Chemical compound C1=C(CS(=O)(=O)NC)C=C2C(CCN(C([2H])([2H])[2H])C([2H])([2H])[2H])=CNC2=C1 KQKPFRSPSRPDEB-XERRXZQWSA-N 0.000 description 24
208000002193 Pain Diseases 0.000 description 20
230000036470 plasma concentration Effects 0.000 description 18
238000001727 in vivo Methods 0.000 description 17
150000001875 compounds Chemical class 0.000 description 15
238000010521 absorption reaction Methods 0.000 description 13
230000000694 effects Effects 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
239000007888 film coating Substances 0.000 description 11
238000009501 film coating Methods 0.000 description 11
150000003890 succinate salts Chemical class 0.000 description 11
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
238000004090 dissolution Methods 0.000 description 8
229940079593 drug Drugs 0.000 description 8
239000007938 effervescent tablet Substances 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
239000006185 dispersion Substances 0.000 description 7
239000007909 solid dosage form Substances 0.000 description 7
239000002904 solvent Substances 0.000 description 7
239000007916 tablet composition Substances 0.000 description 7
230000009471 action Effects 0.000 description 6
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 6
238000000034 method Methods 0.000 description 6
206010021518 Impaired gastric emptying Diseases 0.000 description 5
206010028813 Nausea Diseases 0.000 description 5
230000008693 nausea Effects 0.000 description 5
229940068196 placebo Drugs 0.000 description 5
239000000902 placebo Substances 0.000 description 5
210000002784 stomach Anatomy 0.000 description 5
230000009747 swallowing Effects 0.000 description 5
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
239000004902 Softening Agent Substances 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
235000019658 bitter taste Nutrition 0.000 description 4
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
239000002775 capsule Substances 0.000 description 4
208000001288 gastroparesis Diseases 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
239000000243 solution Substances 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
206010047700 Vomiting Diseases 0.000 description 3
229910052784 alkaline earth metal Inorganic materials 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
235000019700 dicalcium phosphate Nutrition 0.000 description 3
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 3
238000005538 encapsulation Methods 0.000 description 3
239000012530 fluid Substances 0.000 description 3
235000003599 food sweetener Nutrition 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
229960000658 sumatriptan succinate Drugs 0.000 description 3
239000003765 sweetening agent Substances 0.000 description 3
235000019640 taste Nutrition 0.000 description 3
230000008673 vomiting Effects 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
150000007933 aliphatic carboxylic acids Chemical class 0.000 description 2
235000001465 calcium Nutrition 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
235000010216 calcium carbonate Nutrition 0.000 description 2
235000011132 calcium sulphate Nutrition 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
230000001934 delay Effects 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
239000000975 dye Substances 0.000 description 2
239000003974 emollient agent Substances 0.000 description 2
239000007941 film coated tablet Substances 0.000 description 2
239000011888 foil Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
230000030135 gastric motility Effects 0.000 description 2
230000007160 gastrointestinal dysfunction Effects 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
229940090436 imitrex Drugs 0.000 description 2
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
239000001095 magnesium carbonate Substances 0.000 description 2
229910000021 magnesium carbonate Inorganic materials 0.000 description 2
235000014380 magnesium carbonate Nutrition 0.000 description 2
230000000873 masking effect Effects 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
229920003124 powdered cellulose Polymers 0.000 description 2
235000019814 powdered cellulose Nutrition 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
-1 solutions Chemical compound 0.000 description 2
239000008107 starch Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000013589 supplement Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
238000011287 therapeutic dose Methods 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
235000019731 tricalcium phosphate Nutrition 0.000 description 2
238000005303 weighing Methods 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
240000000560 Citrus x paradisi Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
240000009226 Corylus americana Species 0.000 description 1
235000001543 Corylus americana Nutrition 0.000 description 1
235000007466 Corylus avellana Nutrition 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
244000290333 Vanilla fragrans Species 0.000 description 1
235000009499 Vanilla fragrans Nutrition 0.000 description 1
235000012036 Vanilla tahitensis Nutrition 0.000 description 1
235000010358 acesulfame potassium Nutrition 0.000 description 1
239000000619 acesulfame-K Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
235000013736 caramel Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
239000007919 dispersible tablet Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
229940071676 hydroxypropylcellulose Drugs 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000001023 inorganic pigment Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
229960000869 magnesium oxide Drugs 0.000 description 1
235000012245 magnesium oxide Nutrition 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000008368 mint flavor Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000001314 paroxysmal effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000008213 purified water Substances 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
229940013618 stevioside Drugs 0.000 description 1
OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
235000019202 steviosides Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
229940015181 sumatriptan nasal spray Drugs 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
239000000892 thaumatin Substances 0.000 description 1
235000010436 thaumatin Nutrition 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000015149 toffees Nutrition 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20025805A 2001-12-05 2002-12-03 Farmasoytisk sammensetning og anvendelse derav NO329896B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0129117.8A GB0129117D0 (en)	2001-12-05	2001-12-05	Pharmaceutical composition

Publications (3)

Publication Number	Publication Date
NO20025805D0 NO20025805D0 (no)	2002-12-03
NO20025805L NO20025805L (no)	2003-06-06
NO329896B1 true NO329896B1 (no)	2011-01-24

Family

ID=9927051

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20025805A NO329896B1 (no)	2001-12-05	2002-12-03	Farmasoytisk sammensetning og anvendelse derav

Country Status (28)

Country	Link
US (1)	US20050032867A1 (is)
EP (2)	EP1527773A1 (is)
JP (1)	JP3699969B2 (is)
KR (1)	KR100591237B1 (is)
CN (1)	CN1289069C (is)
AR (1)	AR037627A1 (is)
AT (1)	ATE291900T1 (is)
AU (1)	AU2002358602B2 (is)
BR (1)	BR0214497A (is)
CA (1)	CA2469019C (is)
CO (1)	CO5580741A2 (is)
DE (1)	DE60203537T2 (is)
ES (1)	ES2236608T3 (is)
FI (1)	FI20022128A7 (is)
GB (1)	GB0129117D0 (is)
HU (1)	HU229313B1 (is)
IL (1)	IL161997A (is)
IS (1)	IS2481B (is)
MX (1)	MXPA04005420A (is)
MY (1)	MY129314A (is)
NO (1)	NO329896B1 (is)
NZ (1)	NZ532829A (is)
PL (1)	PL194702B1 (is)
PT (1)	PT1450770E (is)
RU (1)	RU2285526C2 (is)
TW (1)	TWI240638B (is)
WO (1)	WO2003047552A2 (is)
ZA (1)	ZA200403849B (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8071128B2 (en)	1996-06-14	2011-12-06	Kyowa Hakko Kirin Co., Ltd.	Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en)	2001-10-04	2016-06-07	Adare Pharmaceuticals, Inc.	Timed, sustained release systems for propranolol
US8367111B2 (en)	2002-12-31	2013-02-05	Aptalis Pharmatech, Inc.	Extended release dosage forms of propranolol hydrochloride
WO2004089365A1 (en)	2003-04-11	2004-10-21	Pfizer Limited	Pharmaceutical combination comprising eletriptan and sodium bicarbonate
CA2527368A1 (en) *	2003-06-06	2004-12-23	Glaxo Group Limited	Pharmaceutical composition
EP3216445A1 (en)	2004-05-28	2017-09-13	Imaginot Pty Ltd.	Oral therapeutic compound delivery system
US8216610B2 (en) *	2004-05-28	2012-07-10	Imaginot Pty Ltd.	Oral paracetamol formulations
US8747895B2 (en)	2004-09-13	2014-06-10	Aptalis Pharmatech, Inc.	Orally disintegrating tablets of atomoxetine
US9884014B2 (en)	2004-10-12	2018-02-06	Adare Pharmaceuticals, Inc.	Taste-masked pharmaceutical compositions
MX2007004741A (es)	2004-10-21	2007-09-07	Eurand Pharmaceuticals Ltd	Composiciones farmaceuticas con sabor enmascarado con formadores de poro gastrosolubles.
US9161918B2 (en)	2005-05-02	2015-10-20	Adare Pharmaceuticals, Inc.	Timed, pulsatile release systems
JP2009517346A (ja)	2005-11-28	2009-04-30	イメイジノットピーティーワイエルティーディー	治療用化合物の経口送達系
RU2313340C1 (ru) *	2006-02-20	2007-12-27	Дмитрий Владимирович Зимин	Лекарственное средство, обладающее противомигренозным действием, и способ его изготовления
WO2007130373A2 (en) *	2006-05-01	2007-11-15	Capricorn Pharma, Inc.	Novel triptan formulations and methods for making them
WO2008039358A2 (en) *	2006-09-30	2008-04-03	Capricorn Pharma Inc.	Resin-complex granulation for water-soluble drugs and associated methods
RU2424803C2 (ru) *	2008-04-07	2011-07-27	Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН (НИИ фармакологии имени В.В.Закусова РАМН)	Фармацевтическая композиция с противомигреневым действием (варианты)
NZ600256A (en)	2009-12-02	2014-05-30	Aptalis Pharma Ltd	Fexofenadine microcapsules and compositions containing them
US11364225B2 (en)	2019-08-21	2022-06-21	Bn Intellectual Properties, Inc.	Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
EP4138787A1 (en) *	2020-04-24	2023-03-01	Astrazeneca AB	Pharmaceutical formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5468504A (en) *	1990-12-21	1995-11-21	Laboratoires Glaxo S.A.	Effervescent pharmaceutical compositions
GB9027827D0 (en) *	1990-12-21	1991-02-13	Glaxo Laboratoires	Pharmaceutical compositions
GB9104890D0 (en) *	1991-03-08	1991-04-24	Glaxo Group Ltd	Compositions
US5460972A (en) *	1991-04-08	1995-10-24	Research Foundation Of The State University Of New York	Ionized magnesium2+ concentrations in biological samples
US6649186B1 (en) *	1996-09-20	2003-11-18	Ethypharm	Effervescent granules and methods for their preparation
GB9704524D0 (en) *	1997-03-05	1997-04-23	Smithkline Beecham Plc	Composition
GB9706089D0 (en) *	1997-03-24	1997-05-14	Scherer Ltd R P	Pharmaceutical composition
AU2640599A (en) *	1998-02-26	1999-09-15	Banyu Pharmaceutical Co., Ltd.	An orally disintegrating composition and its manufacturing method
US6350470B1 (en) *	1998-04-29	2002-02-26	Cima Labs Inc.	Effervescent drug delivery system for oral administration
US6383471B1 (en) *	1999-04-06	2002-05-07	Lipocine, Inc.	Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6264981B1 (en) *	1999-10-27	2001-07-24	Anesta Corporation	Oral transmucosal drug dosage using solid solution
CA2392810A1 (en) *	1999-12-01	2001-06-07	Natco Pharma Limited	A rapid acting freeze dired oral pharmaceutical composition for treating migraine
KR20010107754A (ko) *	2000-05-26	2001-12-07	민경윤	경구투여용 속용정의 제조 방법
US20030008005A1 (en) *	2001-07-05	2003-01-09	R.T. Alamo Ventures, Inc.	Sublingual administration of dihydroergotamine for the treatment of migraine

2001
- 2001-12-05 GB GBGB0129117.8A patent/GB0129117D0/en not_active Ceased
2002
- 2002-12-03 NO NO20025805A patent/NO329896B1/no not_active IP Right Cessation
- 2002-12-03 FI FI20022128A patent/FI20022128A7/fi not_active Application Discontinuation
- 2002-12-03 TW TW091134979A patent/TWI240638B/zh not_active IP Right Cessation
- 2002-12-03 AR ARP020104674A patent/AR037627A1/es unknown
- 2002-12-03 MY MYPI20024534A patent/MY129314A/en unknown
- 2002-12-04 HU HU0402178A patent/HU229313B1/hu unknown
- 2002-12-04 US US10/497,749 patent/US20050032867A1/en not_active Abandoned
- 2002-12-04 KR KR1020047008687A patent/KR100591237B1/ko not_active Expired - Lifetime
- 2002-12-04 PT PT02792887T patent/PT1450770E/pt unknown
- 2002-12-04 BR BR0214497-2A patent/BR0214497A/pt not_active Application Discontinuation
- 2002-12-04 WO PCT/EP2002/013715 patent/WO2003047552A2/en not_active Ceased
- 2002-12-04 DE DE60203537T patent/DE60203537T2/de not_active Expired - Lifetime
- 2002-12-04 CN CNB028244184A patent/CN1289069C/zh not_active Expired - Fee Related
- 2002-12-04 RU RU2004120292/15A patent/RU2285526C2/ru not_active IP Right Cessation
- 2002-12-04 CA CA002469019A patent/CA2469019C/en not_active Expired - Lifetime
- 2002-12-04 NZ NZ532829A patent/NZ532829A/en not_active IP Right Cessation
- 2002-12-04 IL IL16199702A patent/IL161997A/xx active IP Right Grant
- 2002-12-04 AU AU2002358602A patent/AU2002358602B2/en not_active Expired
- 2002-12-04 PL PL02370669A patent/PL194702B1/pl unknown
- 2002-12-04 EP EP05075288A patent/EP1527773A1/en not_active Withdrawn
- 2002-12-04 MX MXPA04005420A patent/MXPA04005420A/es active IP Right Grant
- 2002-12-04 JP JP2003548808A patent/JP3699969B2/ja not_active Expired - Lifetime
- 2002-12-04 AT AT02792887T patent/ATE291900T1/de active
- 2002-12-04 EP EP02792887A patent/EP1450770B1/en not_active Expired - Lifetime
- 2002-12-04 ES ES02792887T patent/ES2236608T3/es not_active Expired - Lifetime
2004
- 2004-05-19 ZA ZA2004/03849A patent/ZA200403849B/en unknown
- 2004-06-03 CO CO04052110A patent/CO5580741A2/es active IP Right Grant
- 2004-06-03 IS IS7293A patent/IS2481B/is unknown

Also Published As

Publication number	Publication date
PL194702B1 (pl)	2007-06-29
CO5580741A2 (es)	2005-11-30
PL370669A1 (en)	2005-05-30
HUP0402178A3 (en)	2011-05-30
GB0129117D0 (en)	2002-01-23
NO20025805D0 (no)	2002-12-03
FI20022128L (fi)	2003-06-06
FI20022128A0 (fi)	2002-12-03
DE60203537T2 (de)	2005-09-15
IS7293A (is)	2004-06-03
MY129314A (en)	2007-03-30
US20050032867A1 (en)	2005-02-10
IL161997A (en)	2005-12-18
ATE291900T1 (de)	2005-04-15
FI20022128A7 (fi)	2003-06-06
EP1527773A1 (en)	2005-05-04
DE60203537D1 (de)	2005-05-04
ZA200403849B (en)	2005-10-26
AR037627A1 (es)	2004-11-17
IS2481B (is)	2008-12-15
HK1069111A1 (en)	2005-05-13
ES2236608T3 (es)	2005-07-16
JP3699969B2 (ja)	2005-09-28
KR100591237B1 (ko)	2006-06-19
PT1450770E (pt)	2005-08-31
RU2004120292A (ru)	2005-04-10
AU2002358602A1 (en)	2003-06-17
CA2469019A1 (en)	2003-06-12
IL161997A0 (en)	2005-11-20
TWI240638B (en)	2005-10-01
JP2005515991A (ja)	2005-06-02
CN1289069C (zh)	2006-12-13
MXPA04005420A (es)	2004-10-11
EP1450770A2 (en)	2004-09-01
HUP0402178A2 (hu)	2005-02-28
CA2469019C (en)	2005-09-13
WO2003047552A2 (en)	2003-06-12
EP1450770B1 (en)	2005-03-30
KR20050044720A (ko)	2005-05-12
HU229313B1 (en)	2013-10-28
TW200304384A (en)	2003-10-01
NO20025805L (no)	2003-06-06
AU2002358602B2 (en)	2005-05-26
BR0214497A (pt)	2004-10-19
NZ532829A (en)	2005-05-27
CN1610539A (zh)	2005-04-27
RU2285526C2 (ru)	2006-10-20
WO2003047552A3 (en)	2003-09-25

Publication	Publication Date	Title
NO329896B1 (no)	2011-01-24	Farmasoytisk sammensetning og anvendelse derav
Jain et al.	2014	A review-formulation & development of orodispersible tablet
KR100846945B1 (ko)	2008-07-17	파라세타몰을 포함하는 연하 정제
AU2011379627B2 (en)	2015-09-10	Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
WO2010087358A1 (ja)	2010-08-05	新規組成物
US20180318228A1 (en)	2018-11-08	Method for a slow release of drugs from orally dissolving capsules
WO2003075919A1 (fr)	2003-09-18	Comprime contenant du chlorhydrate de pilsicainide (voie seche)
US20090264495A1 (en)	2009-10-22	Oral sustained-release pharmaceutical composition of indapamide, production and use thereof
HK1069111B (en)	2005-10-14	Pharmaceutical composition comprising a 5ht1 receptor agonist
EP3174529B1 (en)	2024-12-11	Water dispersible mini-tablets comprising enalapril maleate for the treatment of hypertension in a pediatric population and method of preparation thereof
WO2010123443A1 (en)	2010-10-28	Pharmaceutical composition comprising 4-amino-8-(2-fluoro-6-methoxy-phenyl)-n- propylcinnoline-3-carboxamide hydrogen sulphate.
CN115154429A (zh)	2022-10-11	一种他达拉非口腔崩解组合物

Legal Events

Date	Code	Title	Description
2013-05-21	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: GLAXO GROUP LTD, GB
2023-01-09	MK1K	Patent expired